However, the majority of GC patients with a CPS indicating positive PD-L1 expression exhibited low PD-L1 expression levels (CPS, 1–10) regardless of the presence or absence of FGFR2 genetic alteration (approximately 75% for FGFR2+ and 68.9% for FGFR2−) (Figure 4(f)). Here, FGFR2 is linked to gastric cancer.